Shopping Cart

Expired activity

Please go to the PowerPak homepage and select a course.

ACTIVITY OVERVIEW

Indolent lymphomas are slow-moving and tend to grow more slowly and have fewer signs and symptoms when first diagnosed. Slow-growing or indolent subtypes represent about 40% of all non-Hodgkin lymphoma (NHL) cases. Follicular lymphoma (FL) is the most common subtype of indolent NHL and makes up about 22% of all NHL cases. Recent studies have elucidated that early disease progression in FL occurs in 20% of patients.

This program will review the management of relapsed/refractory (R/R) FL and examine the role of epigenetics within current therapeutic recommendations, given the availability of epigenetic-targeted therapies such as enhancer of zeste homolog 2 (EZH2) inhibitors. Case vignettes will be presented to highlight the pharmacist’s role in the management of FL within the oncology care team, including the oversight of therapeutic plans and the safety evaluation of prescribed medicines for patients with FL.

INTENDED AUDIENCE

This initiative is intended for oncology, specialty, and hospital pharmacists, as well as managed care and other pharmacy health care providers managing patients with FL.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be better able to:

• Review ongoing treatment challenges that occur with hard-to-treat and R/R FL
• Describe the mechanisms of action of treatments that target epigenetic pathways in FL, including EZH2 inhibitors
• Evaluate the most recent efficacy, safety, and pharmacokinetics data on newly approved EZH2 inhibitor therapy for R/R FL
• Integrate pharmacologic management strategies to optimize the use of newly approved epigenetic therapies in R/R FL

FACULTY

Jennifer Amengual, MD
Herbert Irving Assistant Professor of Medicine
Division of Hematology and Oncology
Herbert Irving Comprehensive Cancer Center
Columbia University Irving Medical Center
New York, NY

Peter Campbell, PharmD, BCOP
Clinical Pharmacy Manager, Adult Leukemia
Program Director, PGY2 Oncology Pharmacy Residency
New York-Presbyterian Hospital
Columbia University Irving Medical Center
New York, NY

Anthony Perissinotti, PharmD, BCOP
Clinical Pharmacist Specialist: Hematology
Clinical Team Leader: Hematology/Oncology Pharmacy
Adjunct Clinical Assistant Professor in Pharmacy
University of Michigan
Ann Arbor, MI

DISCLOSURES

Jennifer Amengual, MD, has no relevant financial relationships to disclose.

Peter Campbell, PharmD, BCOP, discloses the following financial relationships: Ad board Pharmacosmos; Ad board Blueprint Medicines; Presentation Honorarium MediCom; Presentation Honorarium PTCE Oncology.

Anthony Perissinotti, PharmD, BCOP, has no relevant financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated

Type of Activity: Application-based

Registration Fee: None

Release Date

October 31, 2021

Expiration Date

October 31, 2022

CONTINUING EDUCATION INFORMATION

The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this application-based activity will provide a statement for 1.5 contact hours credit (0.15 CEUs). Successfully completing the activity and receiving credit includes: 1) viewing the educational activity in its entirety; 2) successfully completing the educational activity post-test; 3) submitting the activity evaluation form. UAN: 0064-9999-21-202-H01-P. It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.

• NABP e-PROFILE ID NUMBER: Pharmacists or pharmacy technicians with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: http://www.nabp.net/programs/cpe-monitor/cpe-monitor-service.
• To receive credit for your participation in this activity, all pharmacists must include their NABP e-Profile ID number, along with their date and month of birth. If incorrect information is provided, this will result in "rejected" status from the CPE Monitor. It is the responsibility of the participant to notify The University of Tennessee (within the 60 day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.